表紙
市場調查報告書

醫藥品有效成分的全球市場:2020年∼2024年

Active Pharmaceutical Ingredients Market by Manufacturing Type and Geography - Forecast and Analysis 2020-2024

出版商 TechNavio (Infiniti Research Ltd.) 商品編碼 250546
出版日期 內容資訊 英文 156 Pages
訂單完成後即時交付
價格
Back to Top
醫藥品有效成分的全球市場:2020年∼2024年 Active Pharmaceutical Ingredients Market by Manufacturing Type and Geography - Forecast and Analysis 2020-2024
出版日期: 2019年12月16日內容資訊: 英文 156 Pages
簡介

全球醫藥品有效成分市場上,開發中國家的API製造方案的演進,類型II原料藥主檔案(DMF)的增加,著重核心競爭力必要性的高漲等成為成長促進因素,在預測期間內預計將以6%以上的年複合成長率擴大。但,API的外包和生產能力利用限制相關疑慮提高,可能妨礙在預測期間內醫藥品有效成分產業的成長。

本報告提供全球醫藥品有效成分市場相關調查分析,市場規模及成長率,市場趨勢,市場的推動要素與課題,市場機會驗證,再加上主要供應商等相關的系統性資訊。

目錄

第1章 摘要整理

第2章 調查範圍

  • 簡介1
  • 簡介2
  • 美金的貨幣換算比率

第3章 市場情形

  • 市場生態系統
  • 市場特徵
  • 市場區隔分析
  • 價值鏈分析

第4章 市場規模

  • 市場定義
  • 市場規模(2019年)
  • 市場規模及預測(2019年∼2024年)
  • 市場預測

第5章 波特的五力分析

  • 買主談判力
  • 供應商談判力
  • 新加入廠商的威脅
  • 替代品的威脅
  • 競爭對手的威脅
  • 市場情況

第6章 客戶形勢

第7章 市場區隔:各製造類型

  • 市場區隔:各製造類型
  • 各製造類型比較:市場規模及預測(2019年∼2024年)
  • 專屬式API
  • 契約API
  • 市場機會:各製造類型

第8章 各地區形勢

  • 各地區市場區隔
  • 各地區比較:市場規模及預測(2019年∼2024年)
  • 亞洲
  • 北美
  • 歐洲
  • 其他地區
  • 主要國家
  • 市場機會

第9章 決策架構

第10章 成長要素與課題

  • 市場成長要素
  • 市場課題

第11章 市場趨勢

  • 老年人口的增加
  • API製造的模式轉移
  • 專利失效的增加

第12章 業者情勢

  • 概要
  • 創造性破壞狀況
  • 競爭方案

第13章 供應商分析

  • 交易廠商
  • 供應商分類
  • 供應商的市場定位
  • Amneal Pharmaceuticals Inc.
  • Cadila Healthcare Ltd.
  • Jazz Pharmaceuticals Plc
  • Lupin Ltd.
  • Mylan NV
  • Novartis AG
  • Pfizer Inc.
  • Sun Pharmaceutical Industries Ltd.
  • Teva Pharmaceutical Industries Ltd.
  • Thermo Fisher Scientific Inc.

第14章 附錄

  • 調查方法
  • 簡稱的清單
  • 供應商的市場定位定義

第15章 關於TECHNAVIO

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: IRTNTR40608

About this market

Technavio's active pharmaceutical ingredients market analysis considers sales from captive API and contract API. Our study also finds the sales of active pharmaceutical ingredients in Asia, Europe, North America, and ROW. In 2019, the contract API segment had a significant market share, and this trend is expected to continue over the forecast period. Factors such as the growing demand for low-cost drugs will play a significant role in the contract API segment to maintain its market position. Also, our global active pharmaceutical ingredients market report looks at factors such as evolving API manufacturing scenarios in developing countries, increasing the number of type II drug master (DMFs), and growing need to focus on core competencies. However, growing concerns regarding outsourced APIs and capacity utilization constraints may hamper the growth of the active pharmaceutical ingredients industry over the forecast period.

Overview

Increasing number of type II drug master files (DMFs)

The market has witnessed a steady rise in the number of DMF filings over the past two decades. This is due to the increasing investments to enhance manufacturing facilities by Asian companies to meet international quality standards. In addition, market players in India are increasingly focusing on achieving compliance with standards laid by various regulatory agencies such as the US FDA, TGA, MHRA, Brazilian Health Regulatory Agency, and SAHPRA. The increasing DMF approvals by regulatory agencies are providing significant growth opportunities for API manufacturers. Such factors will lead to the expansion of the global active pharmaceutical ingredients market at a CAGR of over 6% during the forecast period.

Paradigm shift in API manufacturing

Traditionally, most of the pharmaceutical companies have been relying on their in-house capabilities for the discovery, development, and manufacturing of APIs. However, the captive API manufacturing has seen an overhaul in the last few decades as many pharmaceutical companies are focusing on outsourcing a large share of their research and manufacturing processes to CMOs or other drug manufacturing organizations. The decision to outsource an API depends on several factors, such as industry trends, the cost of acquiring new in-house technologies, and the availability of internal capacity. Outsourcing of API enables innovators as well as generic drug manufacturers to meet aggressive development timelines while capitalizing significant efficiencies in the supply chain. This development is expected to have a positive impact on the overall market growth.

For the detailed list of factors that will drive the global active pharmaceutical ingredients market during the forecast period 2020-2024, view our report.

Competitive Landscape

With the presence of several major players, the global active pharmaceutical ingredients market is fragmented. Technavio's robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading active pharmaceutical ingredients manufacturers, that include Amneal Pharmaceuticals Inc., Cadila Healthcare Ltd., Jazz Pharmaceuticals Plc, Lupin Ltd., Mylan NV, Novartis AG, Pfizer Inc., Sun Pharmaceutical Industries Ltd., Teva Pharmaceutical Industries Ltd., and Thermo Fisher Scientific Inc.

Also, the active pharmaceutical ingredients market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage on all forthcoming growth opportunities.

TABLE OF CONTENTS

PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT

  • 2.1 Preface
  • 2.2 Preface
  • 2.3 Currency conversion rates for US$

PART 03: MARKET LANDSCAPE

  • Market ecosystem
  • Market characteristics
  • Market segmentation analysis
  • Value chain analysis

PART 04: MARKET SIZING

  • Market definition
  • Market sizing 2019
  • Market size and forecast 2019-2024
  • Market outlook

PART 05: FIVE FORCES ANALYSIS

  • Bargaining power of buyers
  • Bargaining power of suppliers
  • Threat of new entrants
  • Threat of substitutes
  • Threat of rivalry
  • Market condition

PART 06: CUSTOMER LANDSCAPE

PART 07: MARKET SEGMENTATION BY MANUFACTURING TYPE

  • Market segmentation by manufacturing type
  • Comparison by manufacturing type
  • Captive API - Market size and forecast 2019-2024
  • Contract API - Market size and forecast 2019-2024
  • Market opportunity by manufacturing type

PART 08: GEOGRAPHIC LANDSCAPE

  • Geographic segmentation
  • Geographic comparison
  • Asia - Market size and forecast 2019-2024
  • North America - Market size and forecast 2019-2024
  • Europe - Market size and forecast 2019-2024
  • ROW - Market size and forecast 2019-2024
  • Key leading countries
  • Market opportunity

PART 09: DECISION FRAMEWORK

PART 10: DRIVERS AND CHALLENGES

  • Market drivers
  • Market challenges

PART 11: MARKET TRENDS

  • Increasing geriatric population
  • Paradigm shift in API manufacturing
  • Increasing patent expiries

PART 12: VENDOR LANDSCAPE

  • Overview
  • Landscape disruption
  • Competitive scenario

PART 13: VENDOR ANALYSIS

  • Vendors covered
  • Vendor classification
  • Market positioning of vendors
  • Amneal Pharmaceuticals Inc.
  • Cadila Healthcare Ltd.
  • Jazz Pharmaceuticals Plc
  • Lupin Ltd.
  • Mylan NV
  • Novartis AG
  • Pfizer Inc.
  • Sun Pharmaceutical Industries Ltd.
  • Teva Pharmaceutical Industries Ltd.
  • Thermo Fisher Scientific Inc.

PART 14: APPENDIX

  • Research methodology
  • List of abbreviations
  • Definition of market positioning of vendors

PART 15: EXPLORE TECHNAVIO

LIST OF EXHIBITS:

  • Exhibit 01: Global pharmaceuticals market
  • Exhibit 02: Segments of global pharmaceuticals market
  • Exhibit 03: Market characteristics
  • Exhibit 04: Market segments
  • Vendors: Key offerings
  • Exhibit 05: Market definition - Inclusions and exclusions checklist
  • Exhibit 06: Market size 2019
  • Exhibit 07: Global market: Size and forecast 2019-2024 ($ billions)
  • Exhibit 08: Global market: Year-over-year growth 2020-2024 (%)
  • Exhibit 09: Five forces analysis 2019
  • Exhibit 10: Five forces analysis 2024
  • Exhibit 11: Bargaining power of buyers
  • Exhibit 12: Bargaining power of suppliers
  • Exhibit 13: Threat of new entrants
  • Exhibit 14: Threat of substitutes
  • Exhibit 15: Threat of rivalry
  • Exhibit 16: Market condition - Five forces 2019
  • Exhibit 17: Customer landscape
  • Exhibit 18: Manufacturing type - Market share 2019-2024 (%)
  • Exhibit 19: Comparison by manufacturing type
  • Exhibit 20: Captive API - Market size and forecast 2019-2024 ($ billions)
  • Exhibit 21: Captive API - Year-over-year growth 2020-2024 (%)
  • Exhibit 22: Contract API - Market size and forecast 2019-2024 ($ billions)
  • Exhibit 23: Contract API - Year-over-year growth 2020-2024 (%)
  • Exhibit 24: Market opportunity by manufacturing type
  • Exhibit 25: Market share by geography 2019-2024 (%)
  • Exhibit 26: Geographic comparison
  • Exhibit 27: Asia - Market size and forecast 2019-2024 ($ billions)
  • Exhibit 28: Asia - Year-over-year growth 2020-2024 (%)
  • Exhibit 29: Top 3 countries in Asia
  • Exhibit 30: North America - Market size and forecast 2019-2024 ($ billions)
  • Exhibit 31: North America - Year-over-year growth 2020-2024 (%)
  • Exhibit 32: Top 3 countries in North America
  • Exhibit 33: Europe - Market size and forecast 2019-2024 ($ billions)
  • Exhibit 34: Europe - Year-over-year growth 2020-2024 (%)
  • Exhibit 35: Top 3 countries in Europe
  • Exhibit 36: ROW - Market size and forecast 2019-2024 ($ billions)
  • Exhibit 37: ROW - Year-over-year growth 2020-2024 (%)
  • Exhibit 38: Top 3 countries in ROW
  • Exhibit 39: Key leading countries
  • Exhibit 40: Market opportunity
  • Exhibit 41: Cumulative number of DMFs filled 2001-2018
  • Exhibit 42: Total WLs issued 2010-2014
  • Exhibit 43: Impact of drivers and challenges
  • Exhibit 44: Vendor landscape
  • Exhibit 45: Landscape disruption
  • Exhibit 46: Vendors covered
  • Exhibit 47: Vendor classification
  • Exhibit 48: Market positioning of vendors
  • Exhibit 49: Amneal Pharmaceuticals Inc. - Vendor overview
  • Exhibit 50: Amneal Pharmaceuticals Inc. - Business segments
  • Exhibit 51: Amneal Pharmaceuticals Inc. - Organizational developments
  • Exhibit 52: Amneal Pharmaceuticals Inc. - Segment focus
  • Exhibit 53: Amneal Pharmaceuticals Inc. - Key offerings
  • Exhibit 54: Amneal Pharmaceuticals Inc. - Key customers
  • Exhibit 55: Cadila Healthcare Ltd. - Vendor overview
  • Exhibit 56: Cadila Healthcare Ltd. - Business segments
  • Exhibit 57: Cadila Healthcare Ltd. - Organizational developments
  • Exhibit 58: Cadila Healthcare Ltd. - Geographic focus
  • Exhibit 59: Cadila Healthcare Ltd. - Key offerings
  • Exhibit 60: Cadila Healthcare Ltd. - Key customers
  • Exhibit 61: Jazz Pharmaceuticals Plc - Vendor overview
  • Exhibit 62: Jazz Pharmaceuticals Plc - Business segments
  • Exhibit 63: Jazz Pharmaceuticals Plc - Organizational developments
  • Exhibit 64: Jazz Pharmaceuticals Plc - Geographic focus
  • Exhibit 65: Jazz Pharmaceuticals Plc - Key offerings
  • Exhibit 66: Jazz Pharmaceuticals Plc - Key customers
  • Exhibit 67: Lupin Ltd. - Vendor overview
  • Exhibit 68: Lupin Ltd. - Business segments
  • Exhibit 69: Lupin Ltd. - Organizational developments
  • Exhibit 70: Lupin Ltd. - Geographic focus
  • Exhibit 71: Lupin Ltd. - Key offerings
  • Exhibit 72: Lupin Ltd. - Key customers
  • Exhibit 73: Mylan NV - Vendor overview
  • Exhibit 74: Mylan NV - Product segments
  • Exhibit 75: Mylan NV - Organizational developments
  • Exhibit 76: Mylan NV - Geographic focus
  • Exhibit 77: Mylan NV - Segment focus
  • Exhibit 78: Mylan NV - Key offerings
  • Exhibit 79: Mylan NV - Key customers
  • Exhibit 80: Novartis AG - Vendor overview
  • Exhibit 81: Novartis AG - Business segments
  • Exhibit 82: Novartis AG - Organizational developments
  • Exhibit 83: Novartis AG - Geographic focus
  • Exhibit 84: Novartis AG - Segment focus
  • Exhibit 85: Novartis AG - Key offerings
  • Exhibit 86: Novartis AG - Key customers
  • Exhibit 87: Pfizer Inc. - Vendor overview
  • Exhibit 88: Pfizer Inc. - Business segments
  • Exhibit 89: Pfizer Inc. - Organizational developments
  • Exhibit 90: Pfizer Inc. - Geographic focus
  • Exhibit 91: Pfizer Inc. - Segment focus
  • Exhibit 92: Pfizer Inc. - Key offerings
  • Exhibit 93: Pfizer Inc. - Key customers
  • Exhibit 94: Sun Pharmaceutical Industries Ltd. - Vendor overview
  • Exhibit 95: Sun Pharmaceutical Industries Ltd. - Business segments
  • Exhibit 96: Sun Pharmaceutical Industries Ltd. - Organizational developments
  • Exhibit 97: Sun Pharmaceutical Industries Ltd. - Geographic focus
  • Exhibit 98: Sun Pharmaceutical Industries Ltd. - Key offerings
  • Exhibit 99: Sun Pharmaceutical Industries Ltd. - Key customers
  • Exhibit 100: Teva Pharmaceutical Industries Ltd. - Vendor overview
  • Exhibit 101: Teva Pharmaceutical Industries Ltd. - Business segments
  • Exhibit 102: Teva Pharmaceutical Industries Ltd. - Organizational developments
  • Exhibit 103: Teva Pharmaceutical Industries Ltd. - Segment focus
  • Exhibit 104: Teva Pharmaceutical Industries Ltd. - Key offerings
  • Exhibit 105: Teva Pharmaceutical Industries Ltd. - Key customers
  • Exhibit 106: Thermo Fisher Scientific Inc. - Vendor overview
  • Exhibit 107: Thermo Fisher Scientific Inc. - Business segments
  • Exhibit 108: Thermo Fisher Scientific Inc. - Organizational developments
  • Exhibit 109: Thermo Fisher Scientific Inc. - Geographic focus
  • Exhibit 110: Thermo Fisher Scientific Inc. - Segment focus
  • Exhibit 111: Thermo Fisher Scientific Inc. - Key offerings
  • Exhibit 112: Thermo Fisher Scientific Inc. - Key customers
  • Exhibit 113: Validation techniques employed for market sizing
  • Exhibit 114: Definition of market positioning of vendors
Back to Top